Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1217
- Registration Number
- NCT00660907
- Locations
- 🇬🇧
Research Site, Trowbridge, United Kingdom
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 994
- Registration Number
- NCT00643851
- Locations
- 🇺🇸
Southeastern Research Associates, Inc., Greenville, South Carolina, United States
🇺🇸Jackson Clinic, Rolling Fork, Mississippi, United States
🇺🇸Community Health Care, Inc., Canal Fulton, Ohio, United States
Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT00562250
- Locations
- 🇦🇷
Local Institution, Vicente Lopez, Buenos Aires, Argentina
Renal Impairment in Type 2 Diabetic Subjects
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00554450
- Locations
- 🇺🇸
Prism Research, St. Paul, Minnesota, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸Elite Research Institute, Miami, Florida, United States
Drug Interaction With Metformin
- Conditions
- Interventions
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00546741
- Locations
- 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
Phase I Multiple-Ascending Dose (Japan)
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00538174
- Locations
- 🇯🇵
Local Institution, Suita, Osaka, Japan
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
- Conditions
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 915
- Registration Number
- NCT00528879
- Locations
- 🇺🇸
Clinical Research Advantage / Desert Clinical Res, Llc, Tempe, Arizona, United States
🇺🇸Raikhel, Marina, Torrance, California, United States
🇺🇸Office Of Dr. Gray, Spokane, Washington, United States
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
- Conditions
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1067
- Registration Number
- NCT00528372
- Locations
- 🇺🇸
Banksville Medical, Pc, Pittsburgh, Pennsylvania, United States
🇺🇸Ritchken & First M.D.'S, San Diego, California, United States
🇺🇸Village Family Practice, Houston, Texas, United States
A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 163
- Registration Number
- NCT00357370
- Locations
- 🇺🇸
Nea Clinic, Jonesboro, Arkansas, United States
🇺🇸Mountain Diabetes And Endocrine Center, Asheville, North Carolina, United States
🇺🇸Research Institute Of Dallas, P.A., Dallas, Texas, United States
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2005-12-08
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 389
- Registration Number
- NCT00263276
- Locations
- 🇵🇷
Local Institution, San Juan, Puerto Rico
🇨🇦Local institution, Bathurst, New Brunswick, Canada
🇺🇸Local Insitution, Edina, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.